Characteristics of circulating immune cells in HBV-related acute-on-chronic liver failure following artificial liver treatment.
Acute-on-chronic liver failure
Artificial liver support system
Hepatitis B
Immunophenotype
Mass cytometry
Journal
BMC immunology
ISSN: 1471-2172
Titre abrégé: BMC Immunol
Pays: England
ID NLM: 100966980
Informations de publication
Date de publication:
25 Nov 2023
25 Nov 2023
Historique:
received:
18
07
2023
accepted:
19
10
2023
medline:
27
11
2023
pubmed:
26
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Liver failure, which is predominantly caused by hepatitis B (HBV) can be improved by an artificial liver support system (ALSS). This study investigated the phenotypic heterogeneity of immunocytes in patients with HBV-related acute-on-chronic liver failure (HBV-ACLF) before and after ALSS therapy. A total of 22 patients with HBV-ACLF who received ALSS therapy were included in the study. Patients with Grade I according to the ACLF Research Consortium score were considered to have improved. Demographic and laboratory data were collected and analyzed during hospitalization. Immunological features of peripheral blood in the patients before and after ALSS were detected by mass cytometry analyses. In total, 12 patients improved and 10 patients did not. According to the immunological features data after ALSS, the proportion of circulating monocytes was significantly higher in non-improved patients, but there were fewer γδT cells compared with those in improved patients. Characterization of 37 cell clusters revealed that the frequency of effector CD8 Changes in effector CD8
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Liver failure, which is predominantly caused by hepatitis B (HBV) can be improved by an artificial liver support system (ALSS). This study investigated the phenotypic heterogeneity of immunocytes in patients with HBV-related acute-on-chronic liver failure (HBV-ACLF) before and after ALSS therapy.
METHODS
METHODS
A total of 22 patients with HBV-ACLF who received ALSS therapy were included in the study. Patients with Grade I according to the ACLF Research Consortium score were considered to have improved. Demographic and laboratory data were collected and analyzed during hospitalization. Immunological features of peripheral blood in the patients before and after ALSS were detected by mass cytometry analyses.
RESULTS
RESULTS
In total, 12 patients improved and 10 patients did not. According to the immunological features data after ALSS, the proportion of circulating monocytes was significantly higher in non-improved patients, but there were fewer γδT cells compared with those in improved patients. Characterization of 37 cell clusters revealed that the frequency of effector CD8
CONCLUSIONS
CONCLUSIONS
Changes in effector CD8
Identifiants
pubmed: 38007423
doi: 10.1186/s12865-023-00579-8
pii: 10.1186/s12865-023-00579-8
pmc: PMC10676598
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Subventions
Organisme : National Science and Technology Major Project
ID : 2018ZX10101-001
Organisme : National Science and Technology Major Project
ID : 2018ZX10101-001
Organisme : National Science and Technology Major Project
ID : 2018ZX10101-001
Organisme : National Science and Technology Major Project
ID : 2018ZX10101-001
Organisme : National Science and Technology Major Project
ID : 2018ZX10101-001
Organisme : National Science and Technology Major Project
ID : 2018ZX10101-001
Organisme : National Science and Technology Major Project
ID : 2018ZX10101-001
Organisme : National Science and Technology Major Project
ID : 2018ZX10101-001
Organisme : Youth Fund Project of Zhejiang Provincial Natural Science Foundation
ID : LQ17H030002
Organisme : Youth Fund Project of Zhejiang Provincial Natural Science Foundation
ID : LQ17H030002
Organisme : Youth Fund Project of Zhejiang Provincial Natural Science Foundation
ID : LQ17H030002
Organisme : Youth Fund Project of Zhejiang Provincial Natural Science Foundation
ID : LQ17H030002
Organisme : Youth Fund Project of Zhejiang Provincial Natural Science Foundation
ID : LQ17H030002
Organisme : Youth Fund Project of Zhejiang Provincial Natural Science Foundation
ID : LQ17H030002
Organisme : Youth Fund Project of Zhejiang Provincial Natural Science Foundation
ID : LQ17H030002
Organisme : Youth Fund Project of Zhejiang Provincial Natural Science Foundation
ID : LQ17H030002
Informations de copyright
© 2023. The Author(s).
Références
Front Immunol. 2021 Feb 25;12:620365
pubmed: 33717119
Front Immunol. 2022 Nov 25;13:1041176
pubmed: 36505417
Nat Methods. 2016 Jun;13(6):493-6
pubmed: 27183440
Lancet. 2009 Feb 14;373(9663):582-92
pubmed: 19217993
Front Immunol. 2021 Apr 02;12:661182
pubmed: 33868313
Hepatol Int. 2022 Dec;16(6):1398-1411
pubmed: 36109429
World J Gastroenterol. 2020 May 28;26(20):2559-2569
pubmed: 32523311
Cold Spring Harb Perspect Biol. 2020 Nov 2;12(11):
pubmed: 32839203
Front Immunol. 2018 Dec 14;9:2948
pubmed: 30619308
Aliment Pharmacol Ther. 2017 Jun;45(11):1413-1426
pubmed: 28345155
Hepatol Res. 2020 Jun;50(6):656-670
pubmed: 32134538
N Engl J Med. 2020 May 28;382(22):2137-2145
pubmed: 32459924
Hepatobiliary Pancreat Dis Int. 2016 Jun;15(3):275-81
pubmed: 27298103
Front Med (Lausanne). 2021 Jul 27;8:689865
pubmed: 34386507
Pediatr Clin North Am. 2008 Jun;55(3):647-68, xi
pubmed: 18501759
Hepatol Int. 2019 Jul;13(4):353-390
pubmed: 31172417
Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4675-4679
pubmed: 29131246
Hepatology. 2007 Sep;46(3):831-40
pubmed: 17680644
J Infect Dis. 2008 Dec 1;198(11):1643-50
pubmed: 18954265
J Hepatol. 2021 Nov;75(5):1104-1115
pubmed: 34090929
Gut. 2017 Mar;66(3):541-553
pubmed: 28053053
Nat Commun. 2017 Jan 09;7:13839
pubmed: 28067223
PLoS One. 2012;7(4):e33998
pubmed: 22529903
J Immunol. 2005 Apr 15;174(8):4678-87
pubmed: 15814692
J Immunol. 2014 Aug 15;193(4):1645-53
pubmed: 25015833
Vox Sang. 2004 Apr;86(3):189-97
pubmed: 15078254
Nat Rev Immunol. 2012 Jan 20;12(2):136-48
pubmed: 22266691
Gastroenterology. 2014 Aug;147(2):473-84.e2
pubmed: 24801349
Mol Med Rep. 2016 Nov;14(5):4837-4843
pubmed: 27748878
J Microbiol Immunol Infect. 2015 Apr;48(2):137-46
pubmed: 24388581
J Exp Med. 2004 Apr 5;199(7):925-36
pubmed: 15051762
Crit Care. 2006;10(6):R169
pubmed: 17156425
Cell. 2006 Feb 24;124(4):815-22
pubmed: 16497590
Clin Immunol. 2019 May;202:40-48
pubmed: 30914281
Biomed Res Int. 2019 Nov 29;2019:3757149
pubmed: 31871940
Lancet. 2019 Sep 7;394(10201):869-881
pubmed: 31498101
Immun Ageing. 2008 Jul 25;5:6
pubmed: 18657274
Front Med. 2018 Jun;12(3):262-268
pubmed: 29441440
JHEP Rep. 2021 Nov 19;4(2):100398
pubmed: 35059620
Pediatr Res. 2013 Apr;73(4 Pt 1):469-75
pubmed: 23269117
J Leukoc Biol. 2006 Jul;80(1):16-23
pubmed: 16684891
J Clin Immunol. 2012 Aug;32(4):877-85
pubmed: 22415432
Nat Rev Immunol. 2004 Aug;4(8):595-602
pubmed: 15286726
Hepatology. 2015 Dec;62(6):1697-709
pubmed: 26361374
Clin Immunol. 2013 Mar;146(3):207-16
pubmed: 23376586
Ther Apher Dial. 2004 Jun;8(3):180-4
pubmed: 15154867
J Hepatol. 2014 Dec;61(6):1385-96
pubmed: 25135860
Int Immunopharmacol. 2021 Jan;90:107120
pubmed: 33162345
Hepatology. 2016 Oct;64(4):1249-64
pubmed: 27483394
J Hepatol. 2016 Jan;64(1):69-78
pubmed: 26325537
Cytometry A. 2020 Dec;97(12):1217-1221
pubmed: 33125816
Front Immunol. 2019 Feb 25;10:293
pubmed: 30873165
Nat Rev Gastroenterol Hepatol. 2016 Mar;13(3):131-49
pubmed: 26837712
Sci Rep. 2021 Apr 5;11(1):7510
pubmed: 33820919
Gastroenterology. 2015 Mar;148(3):603-615.e14
pubmed: 25479139
Front Immunol. 2021 Feb 05;11:619039
pubmed: 33613548
J Clin Invest. 2018 Feb 1;128(2):668-681
pubmed: 29309050
Blood. 2011 Aug 4;118(5):e16-31
pubmed: 21653326
Blood Cells Mol Dis. 2001 Jul-Aug;27(4):731-43
pubmed: 11778657
Hepatology. 2009 May;49(5 Suppl):S13-21
pubmed: 19399811
J Immunother. 2018 Apr;41(3):118-124
pubmed: 29401165
J Clin Lab Anal. 2022 Dec;36(12):e24766
pubmed: 36336888
Blood. 2001 May 15;97(10):3146-51
pubmed: 11342442
Medicine (Baltimore). 2014 Dec;93(28):e338
pubmed: 25526495
Nat Rev Immunol. 2011 Sep 23;11(10):658-71
pubmed: 21941294
Sci Rep. 2016 Dec 15;6:38714
pubmed: 27974825
Immunology. 2017 May;151(1):43-55
pubmed: 28092402
J Immunol. 2005 Jun 1;174(11):6571-6
pubmed: 15905493
PLoS One. 2011;6(6):e21190
pubmed: 21701594
J Gastroenterol Hepatol. 2017 Mar;32(3):677-686
pubmed: 27548078
Hepatol Int. 2017 Sep;11(5):419-428
pubmed: 28639033
Front Cell Infect Microbiol. 2023 Mar 21;13:1107351
pubmed: 37026054
Front Immunol. 2021 Mar 31;12:641362
pubmed: 33868273